BG62239B1 - Приложение на лизозимен димер - Google Patents

Приложение на лизозимен димер Download PDF

Info

Publication number: BG62239B1
Authority: BG; Bulgaria
Prior art keywords: use according; lysozyme; lysozyme dimer; group; klp
Prior art date: 1995-01-13

Application number

BG101709A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101709A (en

Inventor

Witold Kiczka

Original Assignee

Nika Health Products Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-13

Filing date

1997-06-30

Publication date

1999-06-30

1997-06-30 Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited

1998-03-31 Publication of BG101709A publication Critical patent/BG101709A/xx

1999-06-30 Publication of BG62239B1 publication Critical patent/BG62239B1/bg

Links

239000000539 dimer Substances 0.000 title claims abstract description 84
108010014251 Muramidase Proteins 0.000 claims abstract description 91
102000016943 Muramidase Human genes 0.000 claims abstract description 91
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 91
229960000274 lysozyme Drugs 0.000 claims abstract description 91
235000010335 lysozyme Nutrition 0.000 claims abstract description 91
239000004325 lysozyme Substances 0.000 claims abstract description 91
239000000203 mixture Substances 0.000 claims abstract description 34
230000003779 hair growth Effects 0.000 claims abstract description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
230000037396 body weight Effects 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 13
230000002265 prevention Effects 0.000 claims abstract description 11
239000006227 byproduct Substances 0.000 claims abstract description 8
208000010824 fish disease Diseases 0.000 claims abstract description 7
210000000987 immune system Anatomy 0.000 claims abstract description 7
230000000699 topical effect Effects 0.000 claims abstract description 6
208000035475 disorder Diseases 0.000 claims abstract 2
238000011282 treatment Methods 0.000 claims description 53
230000000694 effects Effects 0.000 claims description 31
241001465754 Metazoa Species 0.000 claims description 19
208000004631 alopecia areata Diseases 0.000 claims description 19
241000700605 Viruses Species 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 16
208000015181 infectious disease Diseases 0.000 claims description 12
230000000242 pagocytic effect Effects 0.000 claims description 12
230000008260 defense mechanism Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
230000001413 cellular effect Effects 0.000 claims description 8
208000032839 leukemia Diseases 0.000 claims description 8
230000000813 microbial effect Effects 0.000 claims description 8
230000000638 stimulation Effects 0.000 claims description 8
241000277331 Salmonidae Species 0.000 claims description 7
210000002966 serum Anatomy 0.000 claims description 7
241000257303 Hymenoptera Species 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
230000000241 respiratory effect Effects 0.000 claims description 5
108010075016 Ceruloplasmin Proteins 0.000 claims description 4
102100023321 Ceruloplasmin Human genes 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 3
238000001514 detection method Methods 0.000 claims description 3
208000037824 growth disorder Diseases 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
230000001506 immunosuppresive effect Effects 0.000 claims description 3
239000002674 ointment Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
241000710921 Infectious pancreatic necrosis virus Species 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
241001430294 unidentified retrovirus Species 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 12
201000011510 cancer Diseases 0.000 abstract description 9
208000031295 Animal disease Diseases 0.000 abstract 1
108010005627 KLP602 Proteins 0.000 description 60
235000019688 fish Nutrition 0.000 description 35
241000251468 Actinopterygii Species 0.000 description 33
210000004027 cell Anatomy 0.000 description 18
238000000034 method Methods 0.000 description 18
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 16
241000699670 Mus sp. Species 0.000 description 14
210000004209 hair Anatomy 0.000 description 14
229960003632 minoxidil Drugs 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
239000000178 monomer Substances 0.000 description 12
239000003814 drug Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
210000004761 scalp Anatomy 0.000 description 11
238000001727 in vivo Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
210000001541 thymus gland Anatomy 0.000 description 10
229940079593 drug Drugs 0.000 description 9
230000003308 immunostimulating effect Effects 0.000 description 9
239000000047 product Substances 0.000 description 9
210000000952 spleen Anatomy 0.000 description 9
210000001165 lymph node Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
210000004185 liver Anatomy 0.000 description 7
239000006210 lotion Substances 0.000 description 7
150000003254 radicals Chemical class 0.000 description 7
238000012360 testing method Methods 0.000 description 7
241000282412 Homo Species 0.000 description 6
244000062730 Melissa officinalis Species 0.000 description 6
235000010654 Melissa officinalis Nutrition 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
239000000865 liniment Substances 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
238000011640 AKR mouse Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000001835 viscera Anatomy 0.000 description 5
208000035143 Bacterial infection Diseases 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000037213 diet Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229960001438 immunostimulant agent Drugs 0.000 description 4
239000003022 immunostimulating agent Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
241000607525 Aeromonas salmonicida Species 0.000 description 3
241000256837 Apidae Species 0.000 description 3
208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
102000003896 Myeloperoxidases Human genes 0.000 description 3
108090000235 Myeloperoxidases Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000002816 gill Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000009533 lab test Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
244000052769 pathogen Species 0.000 description 3
238000011160 research Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
201000004384 Alopecia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002498 Beta-glucan Polymers 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241001260012 Bursa Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
108010081750 Reticulin Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
231100000360 alopecia Toxicity 0.000 description 2
238000009341 apiculture Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000009534 blood test Methods 0.000 description 2
238000009535 clinical urine test Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000037189 immune system physiology Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000011707 mineral Substances 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000003797 telogen phase Effects 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
206010049119 Emotional distress Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
241000277275 Oncorhynchus mykiss Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010058096 Pancreatic necrosis Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010065081 Phosphorylase b Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
206010048038 Wound infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000002266 amputation Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001420 bacteriolytic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003588 centroblast Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003889 chemical engineering Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
-1 cytosan Chemical compound 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000002143 encouraging effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000000215 hyperchromic effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
238000009372 pisciculture Methods 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
210000004176 reticulum cell Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000011669 selenium Substances 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Fish Paste Products (AREA)
Enzymes And Modification Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG101709A 1995-01-13 1997-06-30 Приложение на лизозимен димер BG62239B1 (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP95100446		1995-01-13
EP95110638		1995-07-07
PCT/EP1996/000135 WO1996021463A2 (fr)	1995-01-13	1996-01-13	Nouvelles applications du dimere de lysozyme

Publications (2)

Publication Number	Publication Date
BG101709A BG101709A (en)	1998-03-31
BG62239B1 true BG62239B1 (bg)	1999-06-30

Family

ID=26138401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101709A BG62239B1 (bg)	1995-01-13	1997-06-30	Приложение на лизозимен димер

Country Status (37)

Country	Link
EP (2)	EP0804227B1 (fr)
JP (1)	JPH10511974A (fr)
KR (1)	KR100420377B1 (fr)
CN (1)	CN1090506C (fr)
AP (2)	AP628A (fr)
AT (1)	ATE218367T1 (fr)
AU (1)	AU709620B2 (fr)
BA (1)	BA96074A (fr)
BG (1)	BG62239B1 (fr)
BR (1)	BR9606973A (fr)
CA (1)	CA2210091A1 (fr)
CZ (1)	CZ293353B6 (fr)
DE (2)	DE69621589D1 (fr)
DZ (1)	DZ1964A1 (fr)
EA (1)	EA001462B1 (fr)
EE (1)	EE9700154A (fr)
ES (1)	ES2109208T1 (fr)
FI (1)	FI972943L (fr)
GB (1)	GB2311724B (fr)
GE (1)	GEP20012571B (fr)
GR (1)	GR970300047T1 (fr)
HR (1)	HRP960014A2 (fr)
HU (1)	HU223903B1 (fr)
IL (1)	IL116737A (fr)
MA (1)	MA23775A1 (fr)
MD (1)	MD1633C2 (fr)
MY (1)	MY132437A (fr)
NO (1)	NO973203L (fr)
NZ (1)	NZ298432A (fr)
OA (1)	OA10436A (fr)
PL (1)	PL185678B1 (fr)
SK (1)	SK94297A3 (fr)
SV (1)	SV1996000001A (fr)
TN (1)	TNSN96004A1 (fr)
TR (1)	TR199700633T1 (fr)
UA (1)	UA50728C2 (fr)
WO (1)	WO1996021463A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6123937A (en) *	1997-03-14	2000-09-26	Nika Health Products, Limited	Applications of lysozyme dimer
IL139209A0 (en) *	1998-04-27	2001-11-25	Nika Health Products Ltd	Lysozyme dimers and methods utilizing the same
AUPP489798A0 (en) *	1998-07-28	1998-08-20	Mediko Pty Ltd	Hair growth/maintenance compositions and methods
RU2009136424A (ru) *	2007-03-02	2011-04-10	СЕНТ СИМЕОН ЭлДиЭй (US)	Композиция и способ лечения папилломавируса и саркоидов лошадей
CN103518978B (zh) *	2013-10-22	2016-01-13	上海艾魁英生物科技有限公司	新型溶菌酶制剂及其制备方法
CN105828829A (zh) *	2013-12-18	2016-08-03	帝斯曼知识产权资产管理有限公司	用于含角蛋白的组织的包含溶菌酶水解物的组合物
CN104585546B (zh) *	2015-01-20	2019-02-05	上海海洋大学	一种促生长抗应激罗非鱼饲料及其制备方法
CN105707509B (zh) *	2016-01-25	2018-12-28	浙江艾杰斯生物科技有限公司	一种用于防治草鱼烂腮病的饲料添加剂
WO2020099556A1 (fr)	2018-11-14	2020-05-22	Universiteit Antwerpen	Lysozyme oxydé
US20220273733A1 (en) *	2019-07-26	2022-09-01	Evolve Biosystems, Inc.	Nutritive compositions with bioactive proteins
CN111657407A (zh) *	2020-05-14	2020-09-15	上海艾魁英生物科技有限公司	提高断奶仔猪非特异性免疫功能的饲料添加剂、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5533408A (en) *	1978-08-30	1980-03-08	Eisai Co Ltd	Immunity-increasing agent
JPS5543040A (en) *	1978-09-25	1980-03-26	Eisai Co Ltd	Immunity raising agent
DE3230999A1 (de) *	1982-08-20	1984-02-23	Philips Kommunikations Industrie AG, 8500 Nürnberg	Verfahren zur zugriffssteuerung bei einem nachrichtensystem
EP0181634A3 (fr) *	1984-11-14	1987-09-09	Takeda Chemical Industries, Ltd.	Gène synthétique pour lysozyme humaine
RU2061496C1 (ru) *	1985-08-02	1996-06-10	Институт общей патологии и экологии человека	Средство, стимулирующее эритропоэз
JPH01501939A (ja) *	1987-01-28	1989-07-06	オーソ・フアーマシユーチカル・コーポレーシヨン	免疫抑制ペプチドおよび使用法
JPH0649659B2 (ja) *	1988-05-26	1994-06-29	ニカヘルスプロダクツ，リミテッド	抗ウイルス及び抗菌組成物並びに使用方法
WO1991010730A1 (fr) *	1990-01-08	1991-07-25	Nika Health Products Ltd.	Procede de preparation de dimeres de ribonuclease
MC2242A1 (fr) *	1990-01-08	1993-02-23	Nika Health Products Ltd	Procede de preparation de dimeres du lysozyme
PL173978B1 (pl) *	1992-07-13	1998-05-29	Nika Health Products Ltd	Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
RU2082413C1 (ru) *	1993-06-30	1997-06-27	Нижегородский государственный медицинский институт	Способ лечения язвенной болезни двенадцатиперстной кишки
RU2071339C1 (ru) *	1994-07-25	1997-01-10	Щербакова Элеонора Григорьевна	Средство для лечения и профилактики дисбактериоза
RU2123345C1 (ru) *	1997-07-31	1998-12-20	Научно-исследовательский институт детского питания Российской Академии сельскохозяйственных наук	Средство для лечения дисбактериоза

1996
- 1996-01-10 DZ DZ960005A patent/DZ1964A1/fr active
- 1996-01-11 IL IL11673796A patent/IL116737A/xx not_active IP Right Cessation
- 1996-01-11 TN TNTNSN96004A patent/TNSN96004A1/fr unknown
- 1996-01-12 HR HR95110638.4A patent/HRP960014A2/hr not_active Application Discontinuation
- 1996-01-12 MY MYPI96000118A patent/MY132437A/en unknown
- 1996-01-12 SV SV1996000001A patent/SV1996000001A/es unknown
- 1996-01-12 BA BA960074A patent/BA96074A/bs unknown
- 1996-01-12 AP APAP/P/1996/000783A patent/AP628A/en active
- 1996-01-13 EE EE9700154A patent/EE9700154A/xx unknown
- 1996-01-13 DE DE69621589T patent/DE69621589D1/de not_active Expired - Lifetime
- 1996-01-13 FI FI972943A patent/FI972943L/fi unknown
- 1996-01-13 WO PCT/EP1996/000135 patent/WO1996021463A2/fr not_active Ceased
- 1996-01-13 GE GEAP19963815A patent/GEP20012571B/en unknown
- 1996-01-13 JP JP8521448A patent/JPH10511974A/ja active Pending
- 1996-01-13 MD MD97-0244A patent/MD1633C2/ro unknown
- 1996-01-13 PL PL96321546A patent/PL185678B1/pl not_active IP Right Cessation
- 1996-01-13 TR TR97/00633T patent/TR199700633T1/xx unknown
- 1996-01-13 SK SK942-97A patent/SK94297A3/sk unknown
- 1996-01-13 CA CA002210091A patent/CA2210091A1/fr not_active Abandoned
- 1996-01-13 ES ES96900321T patent/ES2109208T1/es active Pending
- 1996-01-13 EP EP96900321A patent/EP0804227B1/fr not_active Expired - Lifetime
- 1996-01-13 EA EA199700101A patent/EA001462B1/ru not_active IP Right Cessation
- 1996-01-13 KR KR1019970704726A patent/KR100420377B1/ko not_active Expired - Fee Related
- 1996-01-13 CZ CZ19972202A patent/CZ293353B6/cs not_active IP Right Cessation
- 1996-01-13 BR BR9606973A patent/BR9606973A/pt not_active Application Discontinuation
- 1996-01-13 EP EP00124590A patent/EP1086703A3/fr not_active Withdrawn
- 1996-01-13 HU HU9801689A patent/HU223903B1/hu not_active IP Right Cessation
- 1996-01-13 DE DE0804227T patent/DE804227T1/de active Pending
- 1996-01-13 AU AU43916/96A patent/AU709620B2/en not_active Ceased
- 1996-01-13 AT AT96900321T patent/ATE218367T1/de not_active IP Right Cessation
- 1996-01-13 NZ NZ298432A patent/NZ298432A/en unknown
- 1996-01-13 UA UA97063430A patent/UA50728C2/uk unknown
- 1996-01-13 CN CN96192331A patent/CN1090506C/zh not_active Expired - Fee Related
- 1996-01-13 GB GB9714354A patent/GB2311724B/en not_active Expired - Fee Related
- 1996-01-13 AP APAP/P/1997/001024A patent/AP871A/en active
- 1996-01-15 MA MA24130A patent/MA23775A1/fr unknown
1997
- 1997-06-30 BG BG101709A patent/BG62239B1/bg unknown
- 1997-07-10 NO NO973203A patent/NO973203L/no not_active Application Discontinuation
- 1997-07-11 OA OA70048A patent/OA10436A/en unknown
- 1997-12-31 GR GR970300047T patent/GR970300047T1/el unknown

Also Published As

Publication number	Publication date
BG101709A (en)	1998-03-31
AP9701024A0 (en)	1997-07-31
AP9600783A0 (en)	1996-04-30
HK1002060A1 (en)	1998-07-31
MA23775A1 (fr)	1996-10-01
SV1996000001A (es)	1997-02-17
EP1086703A2 (fr)	2001-03-28
EE9700154A (et)	1997-12-15
JPH10511974A (ja)	1998-11-17
GR970300047T1 (en)	1997-12-31
TNSN96004A1 (fr)	2005-03-15
FI972943A0 (fi)	1997-07-11
CN1177303A (zh)	1998-03-25
AU4391696A (en)	1996-07-31
AP628A (en)	1998-02-27
BA96074A (bs)	1999-08-02
HU223903B1 (hu)	2005-03-29
GEP20012571B (en)	2001-11-26
MD970244A (en)	1999-05-31
IL116737A0 (en)	1996-05-14
GB9714354D0 (en)	1997-09-10
KR19980701337A (ko)	1998-05-15
EP0804227A2 (fr)	1997-11-05
FI972943A7 (fi)	1997-07-11
GB2311724B (en)	1999-07-21
AU709620B2 (en)	1999-09-02
KR100420377B1 (ko)	2004-05-20
TR199700633T1 (xx)	1998-01-21
DE69621589D1 (de)	2002-07-11
SK94297A3 (en)	1998-01-14
ES2109208T1 (es)	1998-01-16
AP871A (en)	2000-09-10
DE804227T1 (de)	1998-04-09
GB2311724A (en)	1997-10-08
NO973203D0 (no)	1997-07-10
OA10436A (en)	2001-12-07
HUP9801689A2 (hu)	1998-10-28
PL321546A1 (en)	1997-12-08
WO1996021463A2 (fr)	1996-07-18
CA2210091A1 (fr)	1996-07-18
CZ293353B6 (cs)	2004-04-14
DZ1964A1 (fr)	2002-10-15
MY132437A (en)	2007-10-31
EA001462B1 (ru)	2001-04-23
PL185678B1 (pl)	2003-07-31
IL116737A (en)	2000-02-17
WO1996021463A3 (fr)	1996-09-19
NO973203L (no)	1997-07-10
NZ298432A (en)	2001-03-30
EP1086703A3 (fr)	2001-05-02
CZ220297A3 (cs)	1998-02-18
HUP9801689A3 (en)	2000-07-28
BR9606973A (pt)	1999-01-26
CN1090506C (zh)	2002-09-11
EP0804227B1 (fr)	2002-06-05
MD1633B2 (en)	2001-03-31
ATE218367T1 (de)	2002-06-15
UA50728C2 (uk)	2002-11-15
EA199700101A1 (ru)	1997-12-30
FI972943L (fi)	1997-07-11
HRP960014A2 (en)	1997-12-31
MD1633C2 (ro)	2001-10-31

Publication	Publication Date	Title
AP871A (en)	2000-09-10	New applicants of lysozyme dimer.
US6183742B1 (en)	2001-02-06	Applications of lysozyme dimer
KR100289841B1 (ko)	2001-05-15	라이소자임 이량체와 이를 포함하는 조성물
JP5291290B2 (ja)	2013-09-18	化学療法を受けている癌患者の治療方法
RU2647455C1 (ru)	2018-03-15	Композиция, обладающая иммуностимулирующим действием для сублингвального применения
RU2133616C1 (ru)	1999-07-27	Иммунотропное средство
RU2105504C1 (ru)	1998-02-27	Пищевая биологически активная добавка "тинростим-с"
CA2578212A1 (fr)	2006-03-09	Methodes favorisant la guerison de plaies
KR20010101065A (ko)	2001-11-14	표고버섯 균사체 추출물 유래의 ｌａｋ 활성증강물질 및이를 함유하는 ｌａｋ 활성증강용 제제
US20020098171A1 (en)	2002-07-25	New application of lysozyme dimer
CN113952446B (zh)	2023-12-05	生物活性肽在抑制骨髓毒性中的应用
MXPA97005246A (en)	1998-07-03	New applications of dimero de lisoz
RU2801614C1 (ru)	2023-08-11	Способ лечения маститов у лактирующих коров
RU2414223C1 (ru)	2011-03-20	Средство, обладающее иммуностимулирующим и гемостимулирующим действием
Cristina et al.	2007	Propolis' activity on some blood parameters in rats.
RU2077888C1 (ru)	1997-04-27	Способ лечения лучевой болезни у животных
RU2620548C1 (ru)	2017-05-26	Способ профилактики респираторных болезней телят
Chan et al.	2023	Transfer Factors: Properties, Mechanism of Action and Its Clinical Applications
Khudiakova et al.	2019	Effect of periodontal treatment of patients with chronic generalized periodontitis
KR20000003837A (ko)	2000-01-25	롬브리신을 유효성분으로 하는 면역증강제
Murill	2004	Mushrooms and Yeast Treatments
CN103705908A (zh)	2014-04-09	一种含有胸腺五肽的冻干药物组合物及制备方法